The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Petrova N.N.

Saint Petersburg State University

Metabolic syndrome in clinical psychiatric practice

Authors:

Petrova N.N.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(8): 13‑20

DOI: 10.17116/jnevro202412408113

Views: 956

Downloaded: 3

Buy for 300₽
Contact the author
Table of contents

METABOLIC SYNDROME IN CLINICAL PSYCHIATRIC PRACTICE
METABOLIC SYNDROME IN CLINICAL PSYCHIATRIC PRACTICE

To cite this article:

Petrova NN. Metabolic syndrome in clinical psychiatric practice. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(8):13‑20. (In Russ.)
https://doi.org/10.17116/jnevro202412408113

Подписка 2025-2 (S.S. Korsakov Journal of Neurology and Psychiatry)
 
МСФ на ЯМ
Close metadata
Recommended articles:
Cognitive impairments and emotional diso­rders and their correction in peri­menopausal women. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(6):48-53
Controversial issues of diagnosis and theoretical concepts of schi­zophrenia in childhood. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7):17-24
Psychological concepts — design of clinical models of schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7):25-31
Pharmacotherapy of schi­zophrenia: clinical and some age-related aspe­cts. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7):41-50
Clinical systematics of chro­nic delu­sional psychoses in schi­zophrenia and schi­zophrenia-spectrum pathology. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7):65-74
Predictors of effe­ctive complex physiotherapy in patients with skin invo­lution. Rege­nerative Biotechnologies, Preventive, Digi­tal and Predictive Medi­cine. 2024;(1):13-20
Serum uric acid — a meta­bolic marker of non-alcoholic fatty liver disease. Russian Journal of Evidence-Based Gastroenterology. 2024;(2):36-42
Asse­ssment of the condition of organs and tissues of the oral cavity in people with dentition defe­cts against the background of meta­bolic syndrome. Stomatology. 2024;(3):31-38
A personalized application of therapeutic physical factors in patients with meta­bolic syndrome. Rege­nerative Biotechnologies, Preventive, Digi­tal and Predictive Medi­cine. 2024;(2):5-11
Skin alte­rations as possible clinical markers of diabetes mellitus and meta­bolic syndrome. Russian Journal of Preventive Medi­cine. 2024;(7):101-107

A literature review in PubMed and Google databases was performed. Inclusion criteria: randomized clinical trials, meta-analyses and systematic reviews, relevant full-text articles on metabolic syndrome (MS) in patients with schizophrenia. Exclusion criteria: articles of poor quality. The terminology of the article corresponds to that used in the publications included in the review. The review substantiates the relevance of the problem of MS, discloses the concept and discusses its criteria, provides data on the prevalence of MS in patients with schizophrenia, discusses the relationship between MS and schizophrenia, MS and cognitive impairment in schizophrenia, and describes metabolic changes in patients with a first episode of psychosis or early stage schizophrenia. Recommendations on therapeutic tactics in the development of metabolic syndrome in patients with schizophrenia are given.

Keywords:

metabolic syndrome
schizophrenia
therapeutic tactics

Authors:

Petrova N.N.

Saint Petersburg State University

Received:

09.07.2024

Accepted:

17.07.2024

List of references:

  1. Shpilevskaya YuR, Shtonda MV. Metabolic syndrome: modern aspects of diagnosis and treatment. Modern achievements of Belarusian and world medical science and practice. 2021;5:4-8. (In Russ.).
  2. Bloomgarden ZT. Symposium: Debating the Metabolic Syndrome. Medscape Conference Coverage, based on selected sessions. American Diabetes Association 66th Scientific Sessions; June 9-13, 2006, Washington, DC. 
  3. Recommendations for the management of patients with metabolic syndrome. Clinical recommendations of the Ministry of Health of the Russian Federation. 2013;43. (In Russ.). https://mzdrav.rk.gov.ru/file/mzdrav_18042014_Klinicheskie_rekomendacii_Metabolicheskij_sindrom.pdf
  4. Belenkov YN, Privalova EV, Kaplunova VY, et al. Metabolic Syndrome: Development of the Issue, Main Diagnostic Criteria. Rational Pharmacotherapy in Cardiology. 2018;14(5):757-764. (In Russ.). https://doi.org/10.20996/1819-6446-2018-14-5-757-764
  5. Sprecher DL, Pearce GL. How deadly is the «deadly quartet»? A post-CABG evaluation. J Am Coll Cardiol. 2000;36(4):1159-1165. https://doi.org/10.1016/s0735-1097(00)00867-6
  6. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24(4):683-689.  https://doi.org/10.2337/diacare.24.4.683
  7. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37(12):1595-1607. https://doi.org/10.2337/diab.37.12.1595
  8. Reaven G. Syndrome X: 10 years after. Drugs. 1999;58 Suppl 1:19-82.  https://doi.org/10.2165/00003495-199958001-00006
  9. Saharnyj diabet: diagnostika, lechenie, profilaktika. Pod red. I.I. Dedova, M.V. Shestakovoj. M.: MIA, 2011;808. (In Russ.).
  10. Kalashnikova MV. Metabolic syndrome: a modern view of the concept, methods of prevention and treatment. Effective pharmacotherapy. Endocrinology. 2013;55:52-60. (In Russ.). https://umedp.ru/upload/iblock/099/099d630c7a8b1719e0da38ae00ba32f5.pdf
  11. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640-1645. https://doi.org/10.1161/CIRCULATIONAHA.109.192644
  12. Balanova YuA, Imaeva AE, Kutsenko VA, et al. Metabolic syndrome and its associations with sociodemographic and behavioral risk factors in the Russian population aged 25—64 years. Cardiovascular Therapy and Prevention. 2020;19(4):2600. (In Russ.). https://doi.org/10.15829/1728-8800-2020-2600
  13. Verbovoy AF, Verbovaya NI, Dolgikh YuA. Obesity is the basis of metabolic syndrome. Obesity and metabolism. 2021;18(2):142-149. (In Russ.). https://doi.org/10.14341/omet12707
  14. Kytikova OY, Antonyuk MV, Kantur TA, et al. Prevalence and biomarkers in metabolic syndrome. Obesity and metabolism. 2021;18(3):302-312. (In Russ.). https://doi.org/10.14341/omet12704
  15. Surowiec I, Noordam R, Bennett K, et al. Metabolomic and lipidomic assessment of the metabolic syndrome in Dutch middle-aged individuals reveals novel biological signatures separating health and disease. Metabolomics. 2019;15(2):23.  https://doi.org/10.1007/s11306-019-1484-7
  16. Barrea L, Annunziata G, Muscogiuri G, et al. Trimethylamine-N-oxide (TMAO) as Novel Potential Biomarker of Early Predictors of Metabolic Syndrome. Nutrients. 2018;10(12):1971. https://doi.org/10.3390/nu10121971
  17. Gao X, Tian Y, Randell E, et al. Unfavorable Associations Between Serum Trimethylamine N-Oxide and L-Carnitine Levels With Components of Metabolic Syndrome in the Newfoundland Population. Front Endocrinol (Lausanne). 2019;10:168.  https://doi.org/10.3389/fendo.2019.00168
  18. Zhenyukh O, Civantos E, Ruiz-Ortega M, et al. High concentration of branched-chain amino acids promotes oxidative stress, inflammation and migration of human peripheral blood mononuclear cells via mTORC1 activation. Free Radic Biol Med. 2017;104:165-177.  https://doi.org/10.1016/j.freeradbiomed.2017.01.009
  19. Aichler M, Borgmann D, Krumsiek J, et al. N-acyl Taurines and Acylcarnitines Cause an Imbalance in Insulin Synthesis and Secretion Provoking β Cell Dysfunction in Type 2 Diabetes. Cell Metab. 2017;25(6):1334-1347. https://doi.org/10.1016/j.cmet.2017.04.012
  20. Ramakrishanan N, Denna T, Devaraj S, et al. Exploratory lipidomics in patients with nascent Metabolic Syndrome. J Diabetes Complications. 2018;32(8):791-794.  https://doi.org/10.1016/j.jdiacomp.2018.05.014
  21. Novgorodtseva TP, Karaman YK, Zhukova NV, et al. Composition of fatty acids in plasma and erythrocytes and eicosanoids level in patients with metabolic syndrome. Lipids Health Dis. 2011;10(1):82.  https://doi.org/10.1186/1476-511X-10-82
  22. Shim K, Gulhar R, Jialal I. Exploratory metabolomics of nascent metabolic syndrome. J Diabetes Complications. 2019;33(3):212-216.  https://doi.org/10.1016/j.jdiacomp.2018.12.002
  23. Grandl G, Wolfrum C. Hemostasis, endothelial stress, inflammation, and the metabolic syndrome. Semin Immunopathol. 2018;40(2):215-224.  https://doi.org/10.1007/s00281-017-0666-5
  24. Mouton AJ, Li X, Hall ME, et al. Obesity, Hypertension, and Cardiac Dysfunction: Novel Roles of Immunometabolism in Macrophage Activation and Inflammation. Circ Res. 2020;126(6):789-806.  https://doi.org/10.1161/CIRCRESAHA.119.312321
  25. Dini L, Tacconi S, Carata E, et al. Microvesicles and exosomes in metabolic diseases and inflammation. Cytokine Growth Factor Rev. 2020;51:27-39.  https://doi.org/10.1016/j.cytogfr.2019.12.008
  26. Jing Y, Wu F, Li D, et al. Metformin improves obesity associated inflammation by altering macrophages polarization. Mol Cell Endocrinol. 2018;461:256-264.  https://doi.org/10.1016/j.mce.2017.09.025
  27. Han MS, White A, Perry RJ, et al. Regulation of adipose tissue inflammation by interleukin 6. Proc Natl Acad Sci. 2020;117(6):2751-2760. https://doi.org/10.1073/pnas.1920004117
  28. Khodamoradi K, Parmar M, Khosravizadeh Z, et al. The role of leptin and obesity on male infertility. Curr Opin Urol. 2020;30(3):334-339.  https://doi.org/10.1097/MOU.0000000000000762
  29. Shiba CK, Damaso AR, Rhein SO, et al. Interdisciplinary therapy had positive effects on inflammatory state, mediated by leptin, adiponectin, and quality of diet in obese women. Nutr Hosp. 2020;34(3):456-464.  https://doi.org/10.20960/nh.02777
  30. Benrick A, Chanclon B, Micallef P, et al. Adiponectin protects against development of metabolic disturbances in a PCOS mouse model. Proc Natl Acad Sci. 2017;114(34):E7187-E7196. https://doi.org/10.1073/pnas.1708854114
  31. Xiang Y, Zhou W, Duan X, et al. Metabolic Syndrome, and Particularly the Hypertriglyceridemic-Waist Phenotype, Increases Breast Cancer Risk, and Adiponectin Is a Potential Mechanism: A Case-Control Study in Chinese Women. Front Endocrinol (Lausanne). 2020;10:905.  https://doi.org/10.3389/fendo.2019.00905
  32. Lei L, Li K, Li L, et al. Circulating zinc-α2-glycoprotein levels are low in newly diagnosed patients with metabolic syndrome and correlate with adiponectin. Nutr Metab (Lond). 2017;14(1):53.  https://doi.org/10.1186/s12986-017-0210-6
  33. Urbschat A, Thiemens A-K, Mertens C, et al. Macrophage-Secreted Lipocalin-2 Promotes Regeneration of Injured Primary Murine Renal Tubular Epithelial Cells. Int J Mol Sci. 2020;21(6):2038. https://doi.org/10.3390/ijms21062038
  34. Curro D, Vergani E, Bruno C, et al. Plasmatic lipocalin‐2 levels in chronic low‐grade inflammation syndromes: Comparison between metabolic syndrome, total and partial adult growth hormone deficiency. BioFactors. 2020;46(4):629-636.  https://doi.org/10.1002/biof.1628
  35. Mosialou I, Shikhel S, Liu J-M, et al. MC4R-dependent suppression of appetite by bone-derived lipocalin 2. Nature. 2017;543(7645):385-390.  https://doi.org/10.1038/nature21697
  36. Kopec AK, Abrahams SR, Thornton S, et al. Thrombin promotes diet-induced obesity through fibrin-driven inflammation. J Clin Invest. 2017;127(8):3152-3166. https://doi.org/10.1172/JCI92744
  37. Villa CR, Chen J, Wen B, et al. Maternal vitamin D beneficially programs metabolic, gut and bone health of mouse male offspring in an obesogenic environment. In J obes. 2016;40(12):1875-1883. https://doi.org/10.1038/ijo.2016.177
  38. Alicka M, Marycz K. The Effect of Chronic Inflammation and Oxidative and Endoplasmic Reticulum Stress in the Course of Metabolic Syndrome and Its Therapy. Stem Cells Int. 2018;2018:1-13.  https://doi.org/10.1155/2018/4274361
  39. Ganesh S, Ashok AH, Kumar CN, Thirthalli J. Prevalence and determinants of metabolic syndrome in patients with schizophrenia: A systematic review and meta-analysis of Indian studies. Asian J Psychiatr. 2016;22:86-92.  https://doi.org/10.1016/j.ajp.2016.05.006
  40. Khalili F, Moayedi F. Metabolic syndrome in schizophrenic patients: prevalence and findings in Bandar Abbas. International Research Journal of Applied and Basic Sciences. 2015;9(11):1890-1894.
  41. Rezaei O, Khodaie-Ardakani M-R, Mandegar MH, et al. Prevalence of metabolic syndrome among an Iranian cohort of inpatients with schizophrenia. The International Journal of Psychiatry in Medicine. 2009;39(4):451-462. 
  42. Dalvand S, Niksima SH, Meshkani R, et al. Prevalence of metabolic syndrome among iranian population: A systematic review and meta-analysis. Iranian journal of public health. 2017;46(4):456-467. 
  43. Shojaeimotlagh V, Hashiehbaf A, Karami M, et al. Prevalence of metabolic syndrome in Iranian patients with schizophrenia: A systematic review and meta-analysis. Diabetes Metab Syndr. 2019;13(1):143-147.  https://doi.org/10.1016/j.dsx.2018.08.014
  44. Yağcıoğlu AA, Ertuğrul A, Eni N, et al. The prevalence and clinical correlates of metabolic syndrome in patients with schizophrenia: findings from a cohort in Turkey. European archives of psychiatry and clinical neuroscience. 2011;261(1):69-78.  https://doi.org/10.1007/s00406-010-0118-x
  45. Sicras-Mainar A, Maurino J, Ruiz-Beato E, Navarro-Artieda R. Prevalence of metabolic syndrome according to the presence of negative symptoms in patients with schizophrenia. Neuropsychiatric disease and treatment. 2015;11:51-57.  https://doi.org/10.2147/NDT.S75449
  46. Sugai T, Suzuki Y, Yamazaki M, et al. Difference in prevalence of metabolic syndrome between Japanese outpatients and inpatients with schizophrenia: A nationwide survey. Schizophr Res. 2016;171(1-3):68-73.  https://doi.org/10.1016/j.schres.2016.01.016
  47. Greenhalgh AM, Gonzalez-Blanco L, Garcia-Rizo C, et al. Meta-analysis of glucose tolerance, insulin, and insulin resistance in antipsychotic-naive patients with nonaffective psychosis. Schizophr Res. 2017;179:57-63.  https://doi.org/10.1016/j.schres.2016.09.026
  48. Pillinger T, Beck K, Stubbs B, et al. Cholesterol and triglyceride levels in first-episode psychosis: systematic review and meta-analysis. Br J Psychiatry. 2017;211(6):339-349.  https://doi.org/10.1192/bjp.bp.117.200907
  49. Perry BI, McIntosh G, Weich S, et al. The association between first-episode psychosis and abnormal glycaemic control: systematic review and meta-analysis. Lancet Psychiatry. 2016;3(11):1049-1058. https://doi.org/10.1016/S2215-0366(16)30262-0
  50. Misiak B, Stańczykiewicz B, Łaczmański Ł, Frydecka D. Lipid profile disturbances in antipsychotic-naive patients with first-episode non-affective psychosis: A systematic review and meta-analysis. Schizophr Res. 2017;190:18-27.  https://doi.org/10.1016/j.schres.2017.03.031
  51. Flatow J, Buckley P, Miller BJ. Meta-analysis of oxidative stress in schizophrenia. Biol Psychiatry. 2013;74(6):400-409.  https://doi.org/10.1016/j.biopsych.2013.03.018
  52. Pillinger T, D’Ambrosio E, McCutcheon R, et al. Is psychosis a multisystem disorder? A meta-review of central nervous system, immune, cardiometabolic, and endocrine alterations in first-episode psychosis and perspective on potential models. Mol Psychiatry. 2019;24(6):776-794.  https://doi.org/10.1038/s41380-018-0058-9
  53. Aoki R, Saito T, Ninomiya K, et al. Shared genetic components between metabolic syndrome and schizophrenia: Genetic correlation using multipopulation data sets. Psychiatry Clin Neurosci. 2022;76(8):361-366.  https://doi.org/10.1111/pcn.13372
  54. Goh KK, Chen CY, Wu TH, et al. Crosstalk between Schizophrenia and Metabolic Syndrome: The Role of Oxytocinergic Dysfunction. Int J Mol Sci. 2022;23(13):7092. https://doi.org/10.3390/ijms23137092
  55. Alfimov PV, Ryvkin PV, Ladyzhensky MYa, et al. Metabolic syndrome in patients with schizophrenia (literature review). Modern therapy of mental disorders. 2014;3:8-14. (In Russ.).
  56. Kritharides L, Chow V, Lambert TJ. Cardiovascular disease in patients with schizophrenia. Med J Aust. 2017;206(2):91-95.  https://doi.org/10.5694/mja16.00650
  57. Rukavishnikov GV, Kasyanov ED, Zhilyaeva TV, et al. Schizophrenia and cardiometabolic disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(6):132-138. (In Russ.). https://doi.org/10.17116/jnevro2021121061132
  58. Tek C, Kucukgoncu S, Guloksuz S, et al. Antipsychotic-induced weight gain in first-episode psychosis patients: a meta-analysis of differential effects of antipsychotic medications. Early Interv Psychiatry. 2016;10(3):193-202.  https://doi.org/10.1111/eip.12251
  59. Qiu C, Fratiglioni L. A major role for cardiovascular burden in age-related cognitive decline. Nat Rev Cardiol. 2015;12(5):267-277.  https://doi.org/10.1038/nrcardio.2014.223
  60. Bora E, Akdede BB, Alptekin K. The relationship between cognitive impairment in schizophrenia and metabolic syndrome: a systematic review and meta-analysis. Psychol Med. 2017;47(6):1030-1040. https://doi.org/10.1017/S0033291716003366
  61. Kahn RS, Sommer IE, Murray RM, et al. Schizophrenia. Nat Rev Dis Primers. 2015;1:15067. https://doi.org/10.1038/nrdp.2015.67
  62. Millan MJ, Agid Y, Brüne M, et al. Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nat Rev Drug Discov. 2012;11(2):141-168.  https://doi.org/10.1038/nrd3628
  63. Hagi K, Nosaka T, Dickinson D, et al. Association Between Cardiovascular Risk Factors and Cognitive Impairment in People With Schizophrenia: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2021;78(5):510-518.  https://doi.org/10.1001/jamapsychiatry.2021.0015
  64. Davidson M, Caspi A, Noy S. The treatment of schizophrenia: from premorbid manifestations to the first episode of psychosis. Dialogues Clin Neurosci. 2005;7(1):7-16.  https://doi.org/10.31887/DCNS.2005.7.1/mdavidson
  65. Kreyenbuhl J, Record EJ, Palmer-Bacon J. A review of behavioral tailoring strategies for improving medication adherence in serious mental illness. Dialogues Clin Neurosci. 2016;18(2):191-201.  https://doi.org/10.31887/DCNS.2016.18.2/jkreyenbuhl
  66. Correll CU, Højlund M, Graham C, et al. Weight Gain and Metabolic Changes in Patients With First-Episode Psychosis or Early-Phase Schizophrenia Treated With Olanzapine: A Meta-Analysis. Int J Neuropsychopharmacol. 2023;26(7):451-464.  https://doi.org/10.1093/ijnp/pyad029
  67. Zhu Y, Li C, Huhn M, et al. How well do patients with a first episode of schizophrenia respond to antipsychotics: A systematic review and meta-analysis. Eur Neuropsychopharmacol. 2017;27(9):835-844.  https://doi.org/10.1016/j.euroneuro.2017.06.011
  68. Ribeiro ELA, de Mendonça Lima T, Vieira MEB, et al. Efficacy and safety of aripiprazole for the treatment of schizophrenia: an overview of systematic reviews. Eur J Clin Pharmacol. 2018;74(10):1215-1233. https://doi.org/10.1007/s00228-018-2498-1
  69. Pigott TA, Carson WH, Saha AR, et al. Aripiprazole Study Group. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry. 2003;64:1048-1056.
  70. Blonde L, Kan HJ, Gutterman EM, et al. Predicted risk of diabetes and coronary heart disease in patients with schizophrenia: aripiprazole versus standard of care. J Clin Psychiatry. 2008;69(5):741-748.  https://doi.org/10.4088/jcp.v69n0507
  71. Bykov YuV, Bekker RA. Ariprizol, an unique antipsychotic with wide spectrum of therapeutic utility in psychiatry: facts and future perspectives. Psychiatry and Psychopharmacotherapy. 2017;19(4):30-47. (In Russ).
  72. Chipchura DA, Freyberg Z, Edwards CL, et al. Does the Time of Drug Administration Alter the Metabolic Risk of Aripiprazole? Front Psychiatry. 2018;9:494.  https://doi.org/10.3389/fpsyt.2018.00494
  73. Kim SW, et al. Effectiveness of switching to aripiprazole from atypical antipsychotics in patients with schizophrenia. Clin Neuropharmacology. 2009;32(5):243-249.  https://doi.org/10.1097/WNF.0b013e31819a68b5
  74. Liao X, Ye H, Si T. A Review of Switching Strategies for Patients with Schizophrenia Comorbid with Metabolic Syndrome or Metabolic Abnormalities. Neuropsychiatr Dis Treat. 2021;17:453-469.  https://doi.org/10.2147/NDT.S294521
  75. Kerwin R, Millet B, Herman E, et al. A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community treated schizophrenic patients. Schizophrenia Trial of Aripiprazole: (STAR) study. Eur Psychiatry. 2007;2(7):433-443. 
  76. Newcomer JW, Campos JA, Marcus RN, et al. A multicenter, randomized, double blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine. J Clin Psychiatry. 2008;69(7):1046-1056.
  77. Danilov DS. The use of aripiprazole in the treatment of obesity associated with the administration of neuroleptics of the second generation in patients with schizophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2014;114(3):34-40. (In Russ.).
  78. Ostuzzi G, Bertolini F, Tedeschi F, et al. Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 participants. World Psychiatry. 2022;21:295-307.  https://doi.org/10.1002/wps.20972
  79. Andrade C. Cardiometabolic Risks in Schizophrenia and Directions for Intervention, 3: Psychopharmacological Interventions. J Clin Psychiatry. 2016;77(9):e1090-e1094. https://doi.org/10.4088/JCP.16f11128
  80. Fernandez-Egea E, Miller B, Garcia-Rizo C, et al. Metabolic effects of olanzapine in patients with newly diagnosed psychosis. J Clin Psychopharmacol. 2011;31(2):154-159.  https://doi.org/10.1097/JCP.0b013e31820fcea3
  81. Ijaz S, Bolea B, Davies S, et al. Antipsychotic polypharmacy and metabolic syndrome in schizophrenia: a review of systematic reviews. BMC Psychiatry. 2018;18(1):275.  https://doi.org/10.1186/s12888-018-1848-y
  82. Southern Health Nottinghamshire APC guidance. SH CP 111. Antipsychotic Guidelines. Version: 8. Summary. Guidelines or the prescribing of Antipsychotics. Available at: https://www.southernhealth.nhs.uk/EasysiteWeb/getresource.axd?AssetID=43822&type=full&servicetype=Inline

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.